Trials / Terminated
TerminatedNCT05657418
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JS107 | JS107, i.v., q3w |
| COMBINATION_PRODUCT | JS107 combination with Toripalimab | JS107 i.v., q3w combine with Toripalimab |
Timeline
- Start date
- 2022-03-29
- Primary completion
- 2025-01-04
- Completion
- 2025-01-04
- First posted
- 2022-12-20
- Last updated
- 2025-06-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05657418. Inclusion in this directory is not an endorsement.